Related Experiment Videos
Detection of K-ras mutations in resected primary leiomyosarcoma
1Section of Surgical Oncology, Louisiana State University Medical Center, New Orleans 70112, USA.
Summary
K-ras gene mutations are uncommon in leiomyosarcoma, a type of soft-tissue sarcoma. While rare, these mutations may indicate a worse prognosis for patients with this cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- K-ras oncogene mutations are frequent in human cancers.
- Reports on K-ras mutations in soft-tissue sarcoma, specifically leiomyosarcoma, are limited.
- Understanding K-ras mutation prevalence can offer prognostic insights.
Purpose of the Study:
- To determine the frequency of K-ras gene mutations in the first exon of leiomyosarcoma.
- To assess the prognostic significance of K-ras mutations in leiomyosarcoma patients.
Main Methods:
- Fifty-one leiomyosarcoma cases were pathologically reviewed.
- DNA was isolated from tumor tissues.
- Polymerase chain reaction (PCR) and denaturing gradient gel electrophoresis (DGGE) were employed to detect K-ras mutations.
- Sequencing confirmed detected mutations.
Main Results:
- K-ras mutations were detected in 7 out of 51 (14%) leiomyosarcoma specimens.
- Patients with K-ras mutations showed a trend toward shorter median survival (25 months) compared to those without (42 months).
- Tumor stage was a significant prognostic factor, with Stages III and IV having significantly worse survival than Stages I and II.
Conclusions:
- K-ras codon 12 mutations are infrequent in leiomyosarcoma.
- A trend suggests K-ras mutations may be associated with poorer survival outcomes.
- Tumor stage remains a critical prognostic indicator in leiomyosarcoma.